| Quantity | 20 nmol, 50 nmol, 100 nmol, 200 nmol | Inquire | 2 vials | Inquire | 20 nmol, 50 nmol, 100 nmol, 200 nmol |
| Description | The product SIRGT65811WQ is a type of small interfering RNA (siRNA) that targets FTSJ1 gene and regulates the expression of gene. The siRNA interferes with the expression of FTSJ1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. It has The product SIRGT65811WQ is a type of small interfering RNA (siRNA) that targets FTSJ1 gene and regulates the expression of gene. The siRNA interferes with the expression of FTSJ1 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Creative Biolabs offers a range of recombinant cell lines for Immunotherapy discovery and development. | This product is a 34 kDa recombinant human Complement C7 protein Antigen with a N-terminal His6-ABP tag expressed in the E.coli. It is available for Antibody Competition. | The product SIRGT77459WQ-2F is a type of small interfering RNA (siRNA) that targets MAT2B gene and regulates the expression gene. The siRNA interferes with the expression MAT2B gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is The product SIRGT77459WQ-2F is a type of small interfering RNA (siRNA) that targets MAT2B gene and regulates the expression gene. The siRNA interferes with the expression MAT2B gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2_-deoxy-2_-fluoro (2'-F) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |